A new hypothesis: Imatinib affects leukemic stem cells in the same way it affects all other leukemic cells

Blood Cancer Journal

Volumn 1, Issue 5, 2011, Pages

  Tomasetti, C ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ANTIPROLIFERATIVE ACTIVITY; BINDING SITE; CELL POPULATION; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; FUSION GENE; HUMAN; LETTER; LEUKEMIA CELL; PHILADELPHIA 1 CHROMOSOME; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; STEM CELL;

EID: 84860653171     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.17     Document Type: Letter

References (8)

1. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
2. Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010; 24: 1823-1833.
3. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
4. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 11: 1029-1035.
5. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with Interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004. (Pubitemid 36302244)
6. Mahon F-X, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 24: 1823-1833.
7. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer 2008; 112: 837-845. (Pubitemid 351240578)
8. Tomasetti C, Levy D. Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proc Natl Acad Sci USA 2010; 107: 16766-16771.